---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-24-000161"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:38:36.212354+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FDA lifts partial clinical hold on Zentalis' azenosertib studies; enrollment to resume

## Summary
- FDA cleared resumption of enrollment in all ongoing azenosertib studies with no changes to the clinical development plan.
- Partial clinical hold was placed June 18, 2024; lifted after FDA review of comprehensive safety assessment.
- Zentalis on track to present azenosertib monotherapy data and additional updates in Q4 2024.
- CEO cites unwavering confidence in azenosertib's therapeutic index for gynecologic malignancies.

## SEC filing metadata
- accession: 0001725160-24-000161
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000161/0001725160-24-000161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000161/zntl-20240916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-24-000161
- JSON: https://secwatch.observer/filing/0001725160-24-000161.json
- Plain text: https://secwatch.observer/filing/0001725160-24-000161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.